Table 2

Change in GFRe in response to FONT study intervention: Rosiglitazone versus adalimumab

Patient #

Rosiglitazone

Adalimumab


Follow-up interval (months)

ΔGFRe slope*

Follow-up interval (months)

ΔGFRe slope*


Pre

Post

Pre

Post


1

12

21

7.91

6

10

-0.39


2

25

19

0.46

16

6

4.04


3

7

26

-5.73

14

18

-2.28


4

23

20

0.91

11

20

0.12


5

12

20

-4.01

50

17

6.35


6

12

9

1.96

6

17

10.36


7

14

17

6.42

23

16

0


8

12

13

4.23

18

16

1.33


9

24

25

3.58

32

7

0.62


10

25

20

-1.65

23

14

-11.69


11

20

7

3.23


Mean ± SD

16.8 ± 6.4

18.0 ± 6.0

1.72 ± 4.10

20 ± 13

14 ± 5

0.84 ± 5.78


*The change in slope is reported as ml/min/1.73 m2/month

Peyser et al. BMC Nephrology 2010 11:2   doi:10.1186/1471-2369-11-2

Open Data